Locations:
Min Investment:
Max Investment:
Target Investment:
(1999 - 2001)
2017
2017
Digital health and healthcare IT investor focused on opportunities in Oncology, Clinical Trials, and Real-World Evidence (geographic interests in N. America, Europe and Asia). Board responsibilities for: Antidote Technologies (UK), Ayogo Health (CA), Clinithink(UK), and Strata Oncology (US).
2012 - 2017
2012 - 2017
Venture Capital, Private Equity and M&A Advisory (advised minority equity investments, M&A, due diligence, valuation and post-investment strategy).
2010 - 2012
2010 - 2012
- Built and applied valuation models including product & business segment models for DCF valuation, leveraged buyout analysis, precedent acquisitions and comparable public company analysis - Account coverage responsibilities for large cap pharma, biotech & spec pharma, generic pharma, health care services and managed care companies
2005 - 2009
2005 - 2009
Worked in the Health and Life Sciences Strategy Practice where I focused primarily on corporate strategy (including Licensing, Business Development and Mergers & Acquisition) in the Pharmaceuticals industry and operational performance in the Health Payer industry.
2009 - 2009
2009 - 2009
Rotation through Accenture's highly selective international development organization to advise the operating model and global partnership strategy for a global health not for profit.
2001 - 2005
Researched the molecular mechanisms of nicotine addiction through pharmacology studies. Publication: b3 Subunits Promote Expression and Nicotine-Induced Up-Regulation of Human Nicotinic a6* Acetylcholine Receptors Expressed in Transfected Cell Lines